---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-070494"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2026-06-04T20:01:13+00:00"
generated_at: "2026-06-04T20:04:18.080554+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Aclaris shareholders elect directors, approve executive pay at 2026 annual meeting

## Summary
- 80.55% of shares voted; 112,499,671 of 139,663,680 outstanding shares represented.
- Elected Anand Mehra and Maxine Gowen as directors with 83.1M and 84.2M votes for, respectively.
- Advisory vote on named executive officer compensation approved: 83.4M for, 9.7M against.
- Ratification of PricewaterhouseCoopers as auditor passed with 112.3M votes for.
- Broker non-votes of 19.4M on proposals 1 and 2; no broker non-votes on auditor ratification.

## SEC filing metadata
- accession: 0001104659-26-070494
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2026-06-04T20:01:13+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000110465926070494/0001104659-26-070494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000110465926070494/acrs-20260604x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-070494
- JSON: https://secwatch.observer/filing/0001104659-26-070494.json
- Plain text: https://secwatch.observer/filing/0001104659-26-070494.txt

## Key facts
- Shareholder Votes
  Aclaris Therapeutics, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: The stockholders ratified the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000110465926070494/0001104659-26-070494-index.htm
- Shareholder Votes
  Aclaris Therapeutics, Inc. shareholders approved Advisory approval of the compensation of the Company’s named executive officers at the 2026-06-04 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000110465926070494/0001104659-26-070494-index.htm
- Shareholder Votes
  Aclaris Therapeutics, Inc. shareholders approved Election of two nominees to serve as directors until the 2029 annual meeting at the 2026-06-04 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: The stockholders elected two nominees to serve as directors on the Board of Directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000110465926070494/0001104659-26-070494-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.